sh-Polypeptide-1 for Hair Regrowth

Evidence Review created on 09/27/2026 using AI4L + evidence-mcp / ChatGPT 6

Also known as: Basic Fibroblast Growth Factor, bFGF, Fibroblast Growth Factor 2, FGF2, FGF-2, Recombinant Human Basic Fibroblast Growth Factor, rh-bFGF, Human Oligopeptide-3, rh-Polypeptide-1, Heparin-Binding Growth Factor 2, Human Basic Fibroblast Growth Factor, CG-bFGF, BIO-FD&C bFGF

Motivation

Sh-polypeptide-1 is a manufactured version of a growth-factor protein involved in communication between cells. It appears in some scalp products and professional hair treatments because of interest in the signals that control hair follicles and the tissue around them. For adults focused on healthy aging, maintaining hair can be an appearance and quality-of-life goal, separate from extending lifespan.

Research in this area spans tissue repair, laboratory hair biology, scalp application, injections, and hair transplantation. Products may combine several growth factors with vitamins, other peptides, or established hair-loss medication. These differences matter when interpreting what was studied: an ingredient name on a serum and a protein delivered during a clinical procedure describe different forms of exposure.

This review examines the evidence for sh-polypeptide-1 in hair regrowth, the relationship between the named ingredient and studied growth-factor preparations, and the role of delivery and formulation. It also considers adverse effects, quality control, treatment schedules, and ways of measuring meaningful change, with attention to the effort and uncertainty involved in sustained use.

Benefits - Risks - Protocol - Conclusion

These sources cover basic fibroblast growth factor (bFGF or FGF2, a protein signaling cell growth and repair), androgenetic alopecia (pattern hair loss), and mesotherapy (injection of treatment mixtures into skin).

Platelet-rich plasma (a blood preparation concentrated in platelets, the cell fragments involved in clotting and repair) appears in several sources below.

No specific qualifying coverage was identified from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io. Life Extension’s on-site search remained inconclusive, but a separate web search located its growth-factor article.

Grokipedia

Fibroblast growth factor 2

Background on the corresponding signaling protein, rather than a dedicated cosmetic-product evaluation. This reference overview is not evidence that a marketed sh-polypeptide-1 preparation regrows hair.

Examine

No dedicated Examine article for sh-polypeptide-1 was found as of September 27, 2026.

ConsumerLab

No dedicated ConsumerLab article or quality-testing report for sh-polypeptide-1 was found as of September 27, 2026.

Systematic Reviews

These systematic reviews (structured summaries of available studies) cover growth-factor combinations and delivery procedures; none estimates the isolated effect of cosmetic sh-polypeptide-1.

The network meta-analysis (a method combining direct and indirect treatment comparisons) includes randomized controlled trials (studies assigning treatments by chance).

Both potential benefit and delivery-related harm are represented. No ingredient-specific systematic assessment of long-term cancer risk, reproductive safety, or continued topical use was identified.

Mechanism of Action

The United States Food and Drug Administration substance record maps sh-polypeptide-1 to human basic fibroblast growth factor, also called FGF2 (a protein controlling cell growth and tissue repair). It is distinct from epidermal growth factor. Cosmetic names alone do not verify a particular product’s sequence, concentration, purity, or biological activity.

FGF2 activates fibroblast growth factor receptors (cell-surface receivers for growth signals), supported by heparan sulfate (a sugar-rich component of the surrounding tissue). Downstream growth and survival signals can support follicle-associated cells and blood-vessel formation. This is a broad tissue-growth mechanism, not selective suppression of the hormonal drivers of pattern hair loss. The stability review describes these actions and formulation limitations.

More signaling is not necessarily better: du Cros’s mouse experiment found delayed follicle development and cycling after repeated growth-factor injections. Developmental stage, dose, and exposure therefore matter.

Human scalp absorption, tissue distribution, and elimination half-life (time for the amount present to halve) for cosmetic sh-polypeptide-1 have not been established. As a protein, it undergoes protein breakdown rather than a demonstrated liver drug-metabolism pathway. Tissue binding may retain activity locally, while heat and protein-degrading enzymes reduce it. Its roughly 18-kilodalton size (a measure of protein mass) makes reliable delivery across intact skin uncertain; injection and needling create different exposures. Laboratory stability measurements cannot supply a human dosing interval.

Historical Context & Evolution

Basic fibroblast growth factor emerged from research on cell proliferation and tissue repair, rather than from an initial program to treat patterned baldness. The Benington narrative review traces its isolation in the 1970s and subsequent recombinant production. Wound-healing research made locally delivered growth signals attractive for regenerative applications, including hair follicles.

Early hair biology was not uniformly supportive. In 1993 neonatal mouse experiments, repeated growth-factor administration delayed hair appearance and later cycles. Subsequent work explored adult follicles, different doses, and combinations rather than establishing that every exposure promotes growth.

Commercial mixtures brought this approach into hair clinics. Kapoor and colleagues’ QR678/QR678 Neo paper described animal testing, peptide mixtures, and composition patents; the developers’ commercial interests are directly relevant. Later human reports included a large uncontrolled mixture study, while Stefanis et al., 2024 explicitly identified sh-polypeptide-1 in an injected mixture.

The 2022 topical add-on trial and Qu et al.’s controlled injection trial subsequently isolated added growth-factor effects within different background treatments. The evidence has therefore evolved through several distinct preparations and delivery methods. Their shared biological rationale explains interest, but does not make a daily cosmetic serum interchangeable with a pharmaceutical growth factor or an injected multi-ingredient formulation.

Expected Benefits

The regrowth item includes density, thickness, and shedding evidence rather than counting each measurement as a separate benefit. Mixed-product studies include 2,428 uncontrolled participants; developers and treating clinics participated, and absence of a control leaves expectations, concurrent treatment, and selection bias unresolved. No benefit for lifespan, systemic health, permanent follicle restoration, or hair repigmentation is established for this intervention.

High 🟩 🟩 🟩

Hair regrowth as an add-on

Two randomized trials support added bFGF: Liu et al. compared it with minoxidil alone in 80 men; Qu et al. included 80 adults and compared bFGF-enriched platelet-rich plasma with plasma alone or placebo on opposite scalp halves. Hair-growth outcomes favored the added growth factor. This grade describes replicated human add-on outcomes across different preparations and routes, not proof for a standalone cosmetic serum. A 75-person combination trial supports regrowth but cannot isolate bFGF from the blood-derived preparation.

Magnitude: Liu’s abstract reports greater photographic improvement at three and six months; Qu’s reports improved hair counts over plasma alone at six months. Neither abstract supplies an absolute between-group count difference. A network meta-analysis estimated 35.12 additional hairs/cm² for growth factor plus platelet-rich plasma (a preparation concentrated from blood) plus minoxidil versus minoxidil alone; this is the combined regimen’s estimate, not the ingredient’s effect.

Medium 🟩 🟩

No separate benefit reaches Medium: regrowth has replicated controlled add-on findings, while the other human outcomes are indirect or uncontrolled.

Low 🟩

Improved survival of transplanted follicles

A 60-person trial found better graft survival with bovine growth factor during transplantation. This is indirect human evidence for sh-polypeptide-1: the protein source, damaged skin, storage solution, and postoperative regimen differ. It does not demonstrate the same outcome for the human cosmetic ingredient.

Magnitude: Twelve-month follicle survival was 91.1% versus 81.0% for the bovine growth-factor regimen versus control. No corresponding effect size is established for sh-polypeptide-1.

Reduced scalp flaking and inflammation ⭕️ Not Central to Hair Regrowth

Kapoor et al., 2023 reported improvement in 40 adults with seborrheic dermatitis (inflamed, oily, flaky skin) receiving QR678 Neo alongside existing treatments. This uncontrolled, commercially involved developer study concerns scalp symptoms; neither sh-polypeptide-1’s contribution nor a resulting regrowth benefit is isolated.

Magnitude: The mean scalp-flaking score fell from 60 to 12 after eight sessions. Concurrent medicines for fungal infection and skin inflammation and the absence of a control prevent attribution to the peptide.

Speculative 🟨

Benefit-Modifying Factors

  • Formulation and delivery: Protein identity, concentration, stability, and access to follicles are central. Evidence from injections cannot establish equivalent results from intact-skin application. Mixtures also make the contribution of sh-polypeptide-1 uncertain.
  • Genetics: No validated genetic variant predicts response or determines dose. Genetic susceptibility to patterned hair loss does not establish sensitivity to this growth factor.
  • Baseline measurements: Hair density, shaft thickness, and retained follicles define the starting point. No blood growth-factor concentration, iron threshold, or hormone measurement has been validated to predict a sh-polypeptide-1 response.
  • Sex: The topical add-on trial studied men; Qu’s controlled injected add-on trial included 47 men and 33 women. No reliable comparison establishes sex-specific benefit or an isolated-ingredient dosing difference.
  • Hair-loss cause: The strongest human signal concerns patterned hair loss. Scarring, autoimmune hair loss, nutritional deficiency, or treatment-related shedding require separate interpretation; growth-factor mixtures studied in these conditions cannot establish ingredient-specific benefit.
  • Age: Older adults may have longer-standing follicle loss, but this is biological context rather than a validated response rule. Evidence beyond age 65 is particularly sparse, and no age-adjusted effect estimate exists.

Potential Risks & Side Effects

The 80-man add-on trial reported no serious adverse reactions or significant difference in adverse-event frequency. The large uncontrolled mixture study reported no side effects, but neither establishes years-long cancer, reproductive, or systemic safety.

High 🟥 🟥 🟥

No risk reaches High specifically for sh-polypeptide-1: replicated controlled human safety studies isolating this ingredient are unavailable.

Medium 🟥 🟥

Local reactions with invasive delivery

Wu et al. documented brief pain, redness, and pinpoint bleeding after bFGF-containing scalp injections in a randomized trial. This is direct human evidence of procedure-related reactions, without separating the peptide from needling and other ingredients. Cosmetic application to intact skin has a different exposure profile.

Magnitude: Reactions occurred in 3/25 participants (12%) receiving bFGF-enriched platelet-rich plasma and 2/25 (8%) also using minoxidil in Wu’s trial. No major adverse effects were reported; these are regimen-specific rates, not isolated-peptide rates.

Low 🟥

Scarring or worsened hair loss after injections

A systematic review describes scarring and worsened hair loss after varied scalp injections. This is indirect human evidence involving different agents and techniques. Tissue injury may contribute; these reports do not establish toxicity from isolated sh-polypeptide-1.

Magnitude: Not quantified in available studies. The heterogeneous reports do not establish an incidence for sh-polypeptide-1-containing preparations.

Scalp infection after invasive delivery

A scalp mesotherapy case report documents collections of pus, tissue destruction, and subsequent scarring requiring surgery. Contamination or skin penetration can introduce infection. This is indirect procedural evidence from a different preparation, not evidence that isolated sh-polypeptide-1 causes infection.

Magnitude: Not quantified in available studies. An isolated case report cannot estimate the infection rate of sh-polypeptide-1 procedures.

Speculative 🟨

Ingredient-specific allergy or immune reactions

Repeated exposure to a recombinant protein could provoke sensitization. This is a mechanistic concern; no controlled ingredient-specific allergy rate was found, and preservatives or other mixture constituents may instead cause reactions.

Stimulation of abnormal tissue growth

Experiments in melanoma cells (cells from a cancer of pigment-producing skin cells) implicate bFGF in tumor-cell growth. They do not demonstrate that scalp application causes cancer; long-term clinical risk from sh-polypeptide-1 remains unmeasured.

Disruption of normal follicle cycling

Repeated bFGF injections delayed hair cycles in newborn mice. This raises a dose-and-context concern, but does not establish hair-cycle injury in adults using cosmetic products.

Risk-Modifying Factors

  • Genetics: No validated genetic test predicts allergy, tissue-growth effects, or other sh-polypeptide-1 adverse events.
  • Baseline biomarkers: No blood concentration or laboratory cutoff defines safe exposure. Normal routine laboratory results cannot establish local growth-factor safety.
  • Sex and reproduction: No reliable sex-specific risk comparison exists. Pregnancy and breastfeeding exposure data were not identified.
  • Pre-existing conditions: Active scalp inflammation, infection, impaired healing, or suspicious lesions increase concern about invasive exposure or growth stimulation. Cancer-related caution is mechanistic rather than proof of treatment-induced cancer.
  • Age: Older skin, fragile tissue, and multiple medications can complicate needling or injection. No ingredient-specific age threshold or dose correction has been validated.
  • Route and co-ingredients: Broken skin, microneedling, and injection change exposure. Preservatives, solvent systems, other growth factors, and microbial contamination can produce harms unrelated to the named peptide.

Key Interactions & Contraindications

No established ingredient-specific interaction database or approved hair-regrowth contraindication list was found. The following distinguish observed combinations from practical or theoretical cautions.

  • Minoxidil — monitor: Combined topical treatment has human data, but cosmetic-serum compatibility and absorption through recently needled skin were not established. Local irritation can overlap; no validated application-separation interval is available.
  • Clot-prevention medicines — procedural caution: Anticoagulants (medicines slowing clot formation; warfarin, apixaban) and antiplatelets (medicines reducing platelet clumping; aspirin, clopidogrel) can increase bleeding and bruising with skin puncture. This concerns the procedure; no peptide-specific interaction or medication-adjustment schedule is established.
  • Irritating topicals (tretinoin, salicylic acid) — caution: Barrier irritation could increase local reactions or absorption. No interaction trial defines safe simultaneous use or a reliable timing interval.
  • Supplements — unestablished: No specific interaction or additive clinical benefit with biotin, collagen, iron, or saw palmetto has been demonstrated. Their inclusion in a mixture does not prove synergy with sh-polypeptide-1.
  • Other growth-factor procedures — caution: Combining peptide injections, blood-derived preparations, or microneedling changes dose and tissue access. A safe cumulative exposure has not been defined, and adverse effects become harder to attribute.

Populations who should avoid Sh-Polypeptide-1:

  • Known hypersensitivity to the ingredient or formulation: avoidance follows ordinary allergy precautions.
  • Pregnancy, breastfeeding, and people under 18: precautionary exclusions because safety and dosing are unstudied, not proven reproductive toxicity.
  • Active infection, open lesions, or unexplained inflammation at the application site: especially relevant to invasive delivery.
  • Known or suspected malignancy at the intended treatment site: precaution based on growth-factor biology; no validated safe interval after cancer treatment exists.

Risk Mitigation Strategies

  • Route matching: Restricting a cosmetic preparation to its intended intact-skin route avoids untested injection or needling exposure. A cosmetic ingredient list does not demonstrate sterility or injectable suitability.
  • Formulation documentation: Ingredient identity, concentration, lot traceability, expiry, and microbial testing reduce substitution and contamination risk. An activity assay is more informative than a purity claim alone for a growth-factor protein.
  • Local tolerability: A clinician-directed small-area assessment can help identify local reactions before wider exposure; a negative result cannot exclude delayed allergy or prove long-term safety.
  • Skin assessment: Documenting lesions and active inflammation before exposure reduces the chance of applying a growth stimulus to abnormal tissue or introducing material through infected skin.
  • Adverse-event stopping criteria: Persistent burning, swelling, spreading redness, discharge, or new hair-loss patches warrant stopping exposure and assessment. Rapid swelling with breathing difficulty is an emergency rather than a routine tolerability issue.

Therapeutic Protocol

  • No standalone standard: No validated sh-polypeptide-1-only hair-regrowth regimen, maximum dose, or titration schedule was identified. Commercial instructions are product-specific and cannot substitute for a clinical dose-finding study.
  • Studied topical approach: Liu et al. used 3,500 international units of bFGF plus 1 mL of 5% minoxidil twice daily for six months. Biological-activity units cannot be converted into a cosmetic peptide percentage without product-specific assay data.
  • Studied injected approach: Stefanis et al. reported eight DermaHeal Stem C’Rum HL sessions every one or two weeks, following the manufacturer’s protocol. Its several peptides were stated at 10 parts per million; the mixture does not define an isolated-ingredient dose.
  • Developer protocol: Kapoor and Shome’s mixture research describes eight sessions at three-to-four-week intervals. Their composition patents and commercial role warrant explicit consideration; this is a reported professional procedure, not a self-injection protocol.
  • Timing and frequency: No morning-versus-evening advantage is established. Twice-daily topical use belongs to the studied bFGF/minoxidil regimen; intermittent injections belong to different formulations. Neither establishes once-daily or split-dose use of a cosmetic serum.
  • Half-life: Human scalp and systemic half-life (time for the amount present to halve) after cosmetic application are unknown. Laboratory protein breakdown does not establish how long the ingredient remains active in people or justify frequent reapplication.
  • Individualization limits: No genotype, sex, age, blood biomarker, or hormone threshold supports dose adjustment. Evidence in older adults, women receiving the isolated protein, and inflammatory or scarring hair loss remains insufficient.

Discontinuation & Cycling

  • Duration: Trials generally assess treatment over months. Lifelong use, durable benefit after discontinuation, and the need for maintenance sessions have not been established for isolated sh-polypeptide-1.
  • Withdrawal: No physiological withdrawal syndrome has been documented. Return of underlying hair loss after stopping is possible, but its timing and extent have not been quantified for this ingredient.
  • Tapering: No evidence-based taper exists. Serious local reactions provide a reason to stop exposure immediately rather than taper; concurrent minoxidil has its own discontinuation considerations.
  • Cycling: No controlled evidence supports scheduled breaks, prevention of tolerance, or repeat-course intervals. Manufacturer maintenance packages do not establish a biological need for cycling.

Sourcing and Quality

  • Identity: The official substance record links sh-polypeptide-1 with human basic fibroblast growth factor. Epidermal growth factor and bovine growth factor are different preparations; supplier terminology such as “biomimetic” needs sequence and activity documentation.
  • Purity and potency: Useful batch evidence includes identity, concentration, protein integrity, residual host-cell proteins, microbial limits, and retained biological activity through expiry. No independent comparative quality ranking of finished hair products was identified.
  • Formulation: FGF2 instability research makes storage, packaging, vehicle, and post-opening stability consequential. Refrigeration requirements are formulation-specific; laboratory powder instructions cannot be imposed on every stabilized cosmetic.
  • Product examples: DermaHeal Stem C’Rum HL and QR678 Neo occur in published mixture research. Their inclusion identifies studied formulations, not an endorsement of purity, availability, regulatory approval, or interchangeability with current retail products.
  • Invasive products: Sterility, control of inflammatory bacterial contaminants, intended route, and qualified administration become essential when skin is penetrated. A research-use-only vial or cosmetic serum has no demonstrated suitability for injection.

Practical Considerations

  • Time to assessment: The 2022 topical add-on trial assessed photographs at three and six months; mixture studies commonly used about six months. Claims of reliable regrowth within days are unsupported, and topical-serum time to effect is unknown.
  • Common pitfalls: Confusing improved hair feel with new growth, changing several treatments simultaneously, using inconsistent photographs, and assuming every “growth factor” is equivalent can create misleading impressions of efficacy.
  • Regulation: No United States approval for sh-polypeptide-1 as a hair-regrowth treatment was identified. The official ingredient record explicitly states that substance registration does not imply regulatory review or approval; cosmetic marketing likewise does not establish efficacy.
  • Access and cost: Topical mixtures and clinic procedures differ substantially in availability and expense. Repeated clinic sessions add time and cost; no cost-effectiveness evidence establishes a premium product or invasive route as better value.
  • Research incentives: Patent holders, manufacturers, and treating clinics may benefit from adoption. No comparative payer-policy evidence was identified; structural insurance incentives cannot explain these largely commercial cosmetic studies without supporting data.

Interaction with Foundational Habits

  • Sleep: No direct sleep effect or interaction has been demonstrated. Consistent sleep supports general health, but no study shows that sleep duration changes sh-polypeptide-1 efficacy; sleep improvement is not an established consequence of treatment.
  • Nutrition: No direct meal-timing interaction applies to scalp application. Adequate nutrition and correction of documented deficiencies address separate contributors to shedding; extra iron or biotin has no demonstrated peptide-enhancing effect in nutritionally sufficient adults.
  • Exercise: No direct effect on training adaptation or strength is established. Sweating and friction could affect topical retention or irritate recently treated skin; no clinical study defines an exercise-spacing interval for this ingredient.
  • Stress management: Any relationship is indirect through hair-loss burden and stress-associated shedding. No evidence shows that sh-polypeptide-1 lowers stress hormones or that a stress-management technique potentiates its molecular effect; improved appearance is distinct from established mental-health benefit.

Monitoring Protocol & Defining Success

Baseline assessment documents the hair-loss diagnosis, scalp condition, current treatments, standardized photographs, and hair density in a reproducible area. Blood testing is selected for the suspected cause of hair loss, not mandated by the peptide. No functional-medicine blood target has been validated for sh-polypeptide-1 efficacy or safety, so invented “optimal” ranges would be misleading.

An illustrative documentation schedule checks tolerability at two to four weeks and repeats photographs and counts at three and six months. It is not a validated treatment protocol. Meaningful success combines reproducible improvement beyond measurement variation with acceptable tolerability. Consistent photography helps separate regrowth from grooming changes.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Scalp hair density No established target; track hairs/cm² against personal baseline Quantify regrowth Same area and imaging method at baseline, three and six months
Hair shaft diameter No established target; track change from baseline Assess thickening Same device and scalp site; measurement noise can mimic change
Scalp inflammation No established numerical target; track redness, pain, and lesions from baseline Detect local harm Document initially, at two to four weeks, and with new symptoms
Ferritin, if deficiency is suspected No sh-polypeptide-1-specific functional target; track correction of confirmed deficiency Assess another cause Ferritin measures iron stores; inflammation alters interpretation; conventional laboratory ranges vary
Thyroid function, if clinically indicated No peptide-specific functional target; track the diagnosed thyroid disorder Assess another cause Thyroid-stimulating hormone reflects thyroid regulation; interpret with symptoms and the laboratory range
  • Perceived coverage: Scalp visibility and styling ease complement measurements.
  • Shedding and comfort: Record shedding, itch, burning, and pain.
  • Treatment burden: Record adherence, discomfort, and time commitment.

Emerging Research

  • Registry status: Searches on September 27, 2026 for sh-polypeptide-1, bFGF, FGF2, and QR678 with hair/alopecia found no active trial isolating this ingredient. Broad growth-factor/peptide searches contained many unrelated interventions and cannot establish an ingredient-specific development program.
  • Completed registered mixture study: NCT05129800, “Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study,” is completed, observational, and enrolled 72 people. It measured hair density, count, and thickness; Stefanis et al., 2024 reported the results. It is not an ongoing efficacy trial.
  • Isolating contribution: Liu et al., 2022 and Qu et al., 2023 isolate added bFGF within different background treatments. Comparisons of verified cosmetic sh-polypeptide-1 with an identical vehicle could clarify whether these findings transfer to marketed serums or depend on specific protein preparations and delivery.
  • Delivery and durability: Benington et al., 2020 identifies protein instability as a translational limitation. Measurements of retained activity, follicle exposure, and sustained benefit after stopping could strengthen the case for specific products or undermine extrapolation from injections to serums.
  • Biological boundaries: The growth delay in du Cros, 1993 and tumor-cell findings in Becker et al., 1989 support examining dose-dependent harm as well as efficacy. These preclinical findings cannot estimate the clinical risk of cosmetic scalp exposure.
  • Transplantation: Lei et al., 2025 studied bovine growth factor in 60 transplant patients and reported 91.1% versus 81.0% follicle survival at 12 months. Different protein origin and surgical exposure limit transfer to human cosmetic sh-polypeptide-1; this remains a separate research setting.

Conclusion

Sh-polypeptide-1 is a cosmetic ingredient name associated with a human growth-factor protein involved in cell growth and tissue repair. Controlled human studies support adding studied basic fibroblast growth factor preparations to minoxidil or to blood-derived scalp injections. These repeated add-on findings support hair regrowth within the tested settings, while leaving the effectiveness of an isolated cosmetic serum, a particular retail concentration, and permanent reversal of hair loss unresolved.

Mixtures containing the ingredient have also produced encouraging hair measurements and scalp-symptom reports. Their other ingredients and concurrent treatments prevent attribution to this protein. Much of the mixture literature involves developers and treating clinics with commercial interests; the commercial skincare commentary has related sales interests. Large uncontrolled studies do not resolve these limitations.

Temporary pain, redness, and minor bleeding have been recorded with injected growth-factor regimens. More serious scalp injury is documented less directly across varied injected treatments. Ingredient-specific allergy and abnormal tissue growth remain possible but unquantified, with long-term safety insufficiently studied. Product identity, retained biological activity, and delivery method determine how relevant published findings are to a specific preparation.

For proactive adults willing to sustain demanding hair-regrowth routines, the central trade-off is additional benefit in studied add-on settings against uncertainty about individual products and the burden of procedures. Hair regrowth remains distinct from an established health or longevity benefit, and maintenance needs and lasting results remain unresolved.

Top - Benefits - Risks - Protocol